KRAS and pancreatic neoplasm: The study showed that the modified GO could simultaneously deliver siRNA of the HDAC1 and KRas1 genes to the pancreatic cancer cell MIA PaCa-2 with high selectivity, as well as inhibit the expression of HDAC1 and Kras genes.